Baseline characteristics of 221 newly diagnosed AML patients in CR1/CRi1 receiving intensive treatment
| . | HDAC-123, n = 92 (41.6%) . | HDAC-135, n = 129 (58.4%) . | P . | Total, N = 221 (100%) . |
|---|---|---|---|---|
| Age at diagnosis, y | .55 | |||
| Median (IQR) | 46.1 (36.2, 53.4) | 47.6 (37.2, 54.9) | 46.6 (36.5, 54.3) | |
| Range | 19.2-60.6 | 18.7-60.8 | 18.7-60.8 | |
| ECOG at diagnosis, n (%) | .16 | |||
| 0-1 | 65 (75.6) | 106 (83.5) | 171 (80.3) | |
| ≥2 | 21 (24.4) | 21 (16.5) | 42 (19.7) | |
| WBC at diagnosis, ×109/L | .59 | |||
| Median (IQR) | 17.5 (4.1, 76.7) | 13.8 (4.1, 47.7) | 14.1 (4.1, 55.3) | |
| Range | 0.8-236.0 | 0.9-342.0 | 0.8-342.0 | |
| AML status, n (%) | .48 | |||
| De novo | 84 (91.3) | 121 (93.8) | 205 (92.8) | |
| Secondary AML* | 8 (8.7) | 8 (6.2) | 16 (7.2) | |
| Cytogenetic risk, n (%) | .72 | |||
| Favorable | 33 (35.9) | 40 (31.0) | 73 (33.0) | |
| Intermediate | 48 (52.2) | 74 (57.4) | 122 (55.2) | |
| Adverse | 11 (12.0) | 15 (11.6) | 26 (11.8) | |
| ELN 2010 prognosis, n (%) | .96 | |||
| Favorable | 43 (47.8) | 61 (47.7) | 104 (47.7) | |
| Intermediate I/II | 36 (40.0) | 52 (40.6) | 88 (40.4) | |
| Adverse | 11 (12.2) | 15 (11.7) | 26 (11.9) | |
| FLT3-ITD, n (%) | .56 | |||
| Mutation | 17 (29.3) | 22 (25.0) | 107 (73.3) | |
| No mutation | 41 (70.7) | 66 (75.0) | 39 (26.7) | |
| NPM1, n (%) | .28 | |||
| Mutation | 22 (38.6) | 41 (47.7) | 63 (44.1) | |
| No mutation | 35 (61.4) | 45 (52.3) | 80 (55.9) | |
| CEBPA, n (%) | .03 | |||
| Single mutation | 1 (3.3) | 2 (2.7) | 3 (3.5) | |
| Double mutation | 0 (0) | 9 (16.7) | 10 (11.7) | |
| No mutation | 29 (96.7) | 43 (79.6) | 72 (84.7) |
| . | HDAC-123, n = 92 (41.6%) . | HDAC-135, n = 129 (58.4%) . | P . | Total, N = 221 (100%) . |
|---|---|---|---|---|
| Age at diagnosis, y | .55 | |||
| Median (IQR) | 46.1 (36.2, 53.4) | 47.6 (37.2, 54.9) | 46.6 (36.5, 54.3) | |
| Range | 19.2-60.6 | 18.7-60.8 | 18.7-60.8 | |
| ECOG at diagnosis, n (%) | .16 | |||
| 0-1 | 65 (75.6) | 106 (83.5) | 171 (80.3) | |
| ≥2 | 21 (24.4) | 21 (16.5) | 42 (19.7) | |
| WBC at diagnosis, ×109/L | .59 | |||
| Median (IQR) | 17.5 (4.1, 76.7) | 13.8 (4.1, 47.7) | 14.1 (4.1, 55.3) | |
| Range | 0.8-236.0 | 0.9-342.0 | 0.8-342.0 | |
| AML status, n (%) | .48 | |||
| De novo | 84 (91.3) | 121 (93.8) | 205 (92.8) | |
| Secondary AML* | 8 (8.7) | 8 (6.2) | 16 (7.2) | |
| Cytogenetic risk, n (%) | .72 | |||
| Favorable | 33 (35.9) | 40 (31.0) | 73 (33.0) | |
| Intermediate | 48 (52.2) | 74 (57.4) | 122 (55.2) | |
| Adverse | 11 (12.0) | 15 (11.6) | 26 (11.8) | |
| ELN 2010 prognosis, n (%) | .96 | |||
| Favorable | 43 (47.8) | 61 (47.7) | 104 (47.7) | |
| Intermediate I/II | 36 (40.0) | 52 (40.6) | 88 (40.4) | |
| Adverse | 11 (12.2) | 15 (11.7) | 26 (11.9) | |
| FLT3-ITD, n (%) | .56 | |||
| Mutation | 17 (29.3) | 22 (25.0) | 107 (73.3) | |
| No mutation | 41 (70.7) | 66 (75.0) | 39 (26.7) | |
| NPM1, n (%) | .28 | |||
| Mutation | 22 (38.6) | 41 (47.7) | 63 (44.1) | |
| No mutation | 35 (61.4) | 45 (52.3) | 80 (55.9) | |
| CEBPA, n (%) | .03 | |||
| Single mutation | 1 (3.3) | 2 (2.7) | 3 (3.5) | |
| Double mutation | 0 (0) | 9 (16.7) | 10 (11.7) | |
| No mutation | 29 (96.7) | 43 (79.6) | 72 (84.7) |
ECOG, Eastern Cooperative Oncology Group performance status.
Non-de novo AML.